You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,246,513

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,246,513

Title:	Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
Abstract:	The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG. In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a RANKL/OPGbppeptide for use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia.
Inventor(s):	Jensen; Martin Blomberg (Copenhagen O, DK)
Assignee:	RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL (Copenhagen O, DK)
Application Number:	14/909,701
Patent Claims:	1. A method of increasing sperm production in a male subject, comprising: selecting a male subject with spermatogenic failure; and administering to said male subject a therapeutically effective amount of a composition comprising Denosumab or an antigen binding domain thereof, or osteoprotegerin (OPG). 2. The method according to claim 1, wherein the composition comprises Denosumab. 3. The method according to claim 1, wherein the composition comprises a Denosumab antigen binding domain. 4. The method according to claim 1, wherein said method includes treating oligospermia. 5. The method according to claim 1, wherein said method includes treating azoospermia. 6. The method according to claim 1, wherein said composition is administered intravenously or subcutaneously. 7. The method according to claim 1, wherein said composition is administered subcutaneously. 8. The method according to claim 1, wherein said composition, is administered intra-intesticularly or in the genital region. 9. The method according to claim 1, wherein said composition, is administered in the scrotal region. 10. The method according to claim 1, wherein the composition is administered to a male subject who does not suffer from testicular cancer at any stage, which is detectable by histological analysis of a tissue sample of the testis from said subject. 11. The method according to claim 1, wherein said method includes treating oligospermia or azoospermia in male mammals, or increasing sperm production in male mammals. 12. The method according to claim 1, wherein said composition is in a pharmaceutical composition. 13. A method of treating oligospermia or azoospermia in a male mammal, or of increasing sperm production in the male mammal, said method comprising administering a therapeutically effective amount of OPG (osteoprotegerin) or a fusion protein comprising OPG to the male mammal, wherein the male mammal has spermatogenic failure. 14. A method of treating oligospermia or azoospermia in a male mammal, or of increasing sperm production in the male mammal, said method comprising administering a therapeutically effective amount of Denosumab to the male mammal, wherein the male mammal has spermatogenic failure.

Details for Patent 10,246,513

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010	⤷ Try a Trial	2033-08-07
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010	⤷ Try a Trial	2033-08-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.